Fipaxalparant
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Fipaxalparant
- Molecular weight
- 445.52
- Structure (SMILES)
- COc1ccc(C(=O)NC2(C(=O)O)Cc3ccccc3C2)cc1OCCc1cccc(C)c1
- a 003423457
- A-003423457
- a003423457
- A003423457
- czn 001
- CZN-001
- czn001
- CZN001
- fipaxalparant
- Fipaxalparant
- fipaxalparant [INN]
- FIPAXALPARANT [USAN]
- Fipaxalparant [WHO-DD]
- fipaxalparant inn
- fipaxalparant usan
- fipaxalparant who dd
- hzn 825
- hzn 825 bid
- hzn 825 qd
- HZN-825
- HZN-825 BID
- HZN-825 QD
- sar 100842
- Sar-100842
- sar100842
And 2 more, listed on the interactive page.
- CAS registry numbers
- 1195941-38-8
- ChEMBL ID
- CHEMBL3621969
- InChIKey
- SOJDTNUCCXWTMG-UHFFFAOYSA-N
- PubChem compound IDs
- 44481866
- FDA ingredient codes (UNII)
- Y76WZ464EY
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- SAR100842
- Type
- Synthetic organic
Mechanisms of action
- Action
- Antagonist
- Action type
- Antagonist
- Target
- LPA1 receptor
- Gene symbol
- LPAR1
- Protein identifier
- Q92633
- Affinity units
- pIC50
- Condition
- Scleroderma, Diffuse
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000404
- Subject identifier
- D045743
- Condition
- Scleroderma, Systemic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000717
- Subject identifier
- D012595
- Condition
- Idiopathic Pulmonary Fibrosis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000768
- Subject identifier
- D054990
- Condition identifier
- EFO_0000404
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000717
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000768
- Highest recorded phase
- 2
- Condition identifier
- EFO_0006890
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005100
- Highest recorded phase
- 2
- NCT01651143
- NCT04781543
- NCT05626751
- NCT05032066
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 2
- Polar surface area
- 84.86
- Calculated partition coefficient (ALogP)
- 3.98
- Calculated partition coefficient (XLogP)
- 4.9
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 8
- Heavy atoms
- 33
- Molecular formula
- C27H27NO5
- Monoisotopic mass
- 445.18892296
- Natural product
- No
- Recorded assays
- 4
- Active assays
- 2
Active assay types
- Confirmatory
Related records
Trials (4)
- A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis
- A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis
- An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)
- Proof of Biological Activity of SAR100842 in Systemic Sclerosis
In development for (3)
- Diffuse scleroderma Phase 2
- Idiopathic pulmonary fibrosis Phase 2
- Systemic sclerosis Phase 2